| Identification | Back Directory | [Name]
RDNYSJATGQDZQN-DXBWTPJFSA-N | [CAS]
161485-82-1 | [Synonyms]
N-Boc-Dap-Phe-OMe
RDNYSJATGQDZQN-DXBWTPJFSA-N
tert-Butyl (S)-2-((1R,2R)-1-methoxy-3-(((S)-1-methoxy-1-oxo-3-phenylpropan-2-yl)amino)-2-methyl-3-ox
tert-butyl (S)-2-((1R,2R)-1-methoxy-3-(((S)-1-methoxy-1-oxo-3-phenylpropan-2-yl)amino)-2-methyl-3-oxopropyl)pyrrolidine-1-carboxylate
(S)-tert-butyl 2-((1R,2R)-1-methoxy-3-(((S)-1-methoxy-1-oxo-3-phenylpropan-2-yl)amino)-2-methyl-3-oxopropyl)pyrrolidine-1-carboxylate
1-Pyrrolidinecarboxylic acid, 2-[(1R,2R)-1-methoxy-3-[[(1S)-2-methoxy-2-oxo-1-(phenylmethyl)ethyl]amino]-2-methyl-3-oxopropyl]-, 1,1-dimethylethyl ester, (2S)- | [Molecular Formula]
C24H36N2O6 | [MDL Number]
MFCD28387091 | [MOL File]
161485-82-1.mol | [Molecular Weight]
448.55 |
| Hazard Information | Back Directory | [Uses]
MMAF intermediate 1 is an intermediate in the synthesis of MMAF (HY-15579). MMAF (Monomethylauristatin F) is a potent inhibitor of tubulin polymerization and the cytotoxic (ADC Cytotoxin) component of classic antibody drug conjugates (ADCs), such as Vorsetuzumab mafodotin and SGN-CD19A[1]. | [References]
[1] Lee JW, et al. EphA2 targeted chemotherapy using an antibody drug conjugate in endometrial carcinoma. Clin Cancer Res. 2010 May 1;16(9):2562-70. [Content Brief] DOI:10.1158/1078-0432.CCR-10-0017 |
|
|